Phosphodiesterase 4 inhibitors for chronic obstructive pulmonary disease (Q24202545)

PubMed

PubMed publication ID

25 October 2023

Jimmy Chong

1

Jimmy

Chong

1 reference

PubMed

PubMed publication ID

24190161

25 October 2023

Bonnie Leung

series ordinal

2

author given names

Bonnie

author last names

Leung

1 reference

PubMed

PubMed publication ID

24190161

Cochrane Database of Systematic Reviews

25 October 2023

publication date

4 November 2013

0 references

published in

0 references

cites work

Cilomilast for COPD: results of a 6-month, placebo-controlled study of a potent, selective inhibitor of phosphodiesterase 4.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002309.PUB4

Cilomilast, a selective phosphodiesterase-4 inhibitor for treatment of patients with chronic obstructive pulmonary disease: a randomised, dose-ranging study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002309.PUB4

Roflumilast--an oral anti-inflammatory treatment for chronic obstructive pulmonary disease: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002309.PUB4

Reduction of exacerbations by the PDE4 inhibitor roflumilast - the importance of defining different subsets of patients with COPD

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002309.PUB4

Roflumilast in Asian patients with COPD: A randomized placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002309.PUB4

Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002309.PUB4

Does a single dose of the phosphodiesterase 4 inhibitor, cilomilast (15 mg), induce bronchodilation in patients with chronic obstructive pulmonary disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002309.PUB4

Reduction in sputum neutrophil and eosinophil numbers by the PDE4 inhibitor roflumilast in patients with COPD

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002309.PUB4

A controlled trial of 6-weeks' treatment with a novel inhaled phosphodiesterase type-4 inhibitor in COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002309.PUB4

COPD, a multicomponent disease: implications for management

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002309.PUB4

Theophylline: new perspectives for an old drug

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002309.PUB4

Phosphodiesterase inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002309.PUB4

Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002309.PUB4

Minimal clinically important differences in COPD lung function

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002309.PUB4

Cyclic nucleotide phosphodiesterases

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002309.PUB4

Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002309.PUB4

Antiinflammatory effects of the phosphodiesterase-4 inhibitor cilomilast (Ariflo) in chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002309.PUB4

Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002309.PUB4

Phosphodiesterase isozymes: molecular targets for novel antiasthma agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002309.PUB4

Ariflo (SB 207499), a second generation phosphodiesterase 4 inhibitor for the treatment of asthma and COPD: from concept to clinic

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002309.PUB4

PDE4 inhibitors in COPD--a more selective approach to treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002309.PUB4

Cardiovascular safety in patients receiving roflumilast for the treatment of COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002309.PUB4

Effect of 1-Year Treatment with Roflumilast in Severe Chronic Obstructive Pulmonary Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002309.PUB4

Roflumilast with long-acting 2-agonists for COPD: influence of exacerbation history

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002309.PUB4

Chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002309.PUB4

7 January 2021

St. George's Respiratory Questionnaire: MCID

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002309.PUB4

7 January 2021

Physiological effects of roflumilast at rest and during exercise in COPD

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002309.PUB4

7 January 2021

Left atrial dysfunction in patients with atrial fibrillation after successful rhythm control for > 3 months

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002309.PUB4

7 January 2021